Paclitaxel - A tool to prevent stenosis in vascular access for haemodialysis?

Blood Purification

Volumn 24, Issue 3, 2006, Pages 287-288

  Konner, Klaus ^a  

^a NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ETHYLENE VINYL ACETATE COPOLYMER; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONTROLLED STUDY; DISEASE MODEL; DRUG DELIVERY SYSTEM; EDITORIAL; HEMODIALYSIS; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; STENOSIS; SWINE; TREATMENT OUTCOME; VASCULAR ACCESS; VEIN ANASTOMOSIS;

ANIMALS; ARTERIOVENOUS SHUNT, SURGICAL; CONSTRICTION, PATHOLOGIC; GRAFT OCCLUSION, VASCULAR; HUMANS; PACLITAXEL; RENAL DIALYSIS; SWINE;

EID: 33744499191     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000091345     Document Type: Editorial

References (4)

1. Czuba ZP, Krol W, Hasinski P, Nowowiejska A: The effects of taxol (paclitaxel) on chemiluminescence of neutrophils, macrophages and J.774.2 cell line. Acta Biochem Pol 1998;45:103-106.
2. Heller PF: Paclitaxel and arterial smooth muscle cell proliferation. Circulation 1998;97:1651.
3. Hong MK, Komowski R, Bramwell O, Ragheb AO, Leon MB: Paclitaxel-coated Gianturco-Roubin II (GRII) stents reduce neointimal hyperplasia in a porcine coronary in-stent restenosis model. Coron Artery Dis 2001;12:513-515.
4. Kelly B, Melhem M, Desai P, Kasting J, Zhang J, Li J, Heffelfinger S, Rudich S, Roy-Chaudhury P: Perivascular paclitaxel polymers reduce neointimal hyperplasia and venous stenosis in PTFE arteriovenous grafts: a solution for hemodialysis vascular access dysfunction? (Abstract) J Am Soc Nephrol 2004;15:25A-26A.